Robert Wicke

Robert is currently CEO of Halo Labs, a life science company specializing in high-throughput protein characterization and identification. Before Halo, Robert was General Manager of Pall ForteBio responsible for growing the company from $20M to $50M+ in four years. Robert was also the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, responsible for all instrumentation R&D across Pall worldwide.

Robert was VP of Product Development and Operations for ForteBio from 2007 to 2012 where he helped grow the company 10x in four years and then exit the company for over $160M. Before that, Robert was at Molecular Devices Corporation, where he was Vice President of Product Development, being on the executive team that helped the $615M acquisition by MDS. Previously he was at Axon Instruments, Inc. for 13 years, as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and was part of the $140+ million acquisition by Molecular Devices.